EXTON, Pa., April 1, 2004 (PRIMEZONE) -- ViroPharma, Inc. (Nasdaq:VPHM) announced today the appointment of William C. Roberts as director, corporate communications.
"As ViroPharma goes forward, it will be essential that we selectively add new members to management who we expect to contribute meaningfully to the future of our growing company. The appointment of Will is the first of such additions," commented Michel de Rosen, ViroPharma's chief executive officer. "Will's 12 years of experience in science and communications at one of the most successful companies in biotechnology will be valuable to us, and his depth of industry knowledge coupled with his analytical abilities will serve the investment community, and ViroPharma, well. We are excited to have him join our company, and count on him to effectively represent the company and communicate our story to the financial community."
Mr. Roberts joins the company after 12 years with MedImmune, Inc., the last six of which were in the corporate communications department. He was responsible for the management of MedImmune's investor communications program. He spent the first six years of his tenure at MedImmune as a scientist in vaccine discovery, in areas including HIV, Lyme disease and cancer. Prior to joining MedImmune, he worked as staff in the genetics department of the University of Virginia. Mr. Roberts holds a master's of business administration from the Keller School of Business and a bachelor's degree in biology from the University of Virginia.
ViroPharma Incorporated is committed to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma is currently focused on drug development activities in viral diseases including cytomegalovirus (CMV) and hepatitis C (HCV).